Julie Eastland
Lantheus HoldingsAbout Julie Eastland
Julie Eastland (age 60) joined the Lantheus Board in September 2024 as an independent director and serves on the Audit Committee. She is President & CEO and a Director of Zentalis Corporation, and is recognized by Lantheus as having audit and financial expertise suitable for Audit Committee service. She holds a B.S. in Finance (Colorado State University) and an M.B.A. (Heriot-Watt University, University of Edinburgh) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Harpoon Therapeutics (NASDAQ: HARP) | Chief Executive Officer | Nov 2021 – Mar 2024 (company acquired by Merck) | Led sale to Merck; previously Audit Chair (2018–2021) |
| Rainier Therapeutics (private) | Chief Financial & Business Officer | 2018 – 2020 | Finance and BD leadership |
| Cascadian Therapeutics (NASDAQ: CASC) | Chief Business Officer & Chief Financial Officer | Sep 2010 – Mar 2018 (acquired by Seattle Genetics) | Finance/strategy through M&A outcome |
| VLST Corporation (private) | CFO & VP Finance and Administration | Jan 2006 – Sep 2010 | Finance leadership |
| Dendreon (NASDAQ: DNDN) | VP Strategic Planning | Oct 2000 – Oct 2005 | Corporate strategy |
| Amgen (NASDAQ: AMGN) | Controller | Mar 1996 – Apr 1998 | Accounting leadership |
External Roles
| Company | Role | Tenure/Status | Committees |
|---|---|---|---|
| Zentalis Corporation | President & CEO; Director | Current | — |
| Dynavax Technologies (NASDAQ: DVAX) | Independent Director | Since Jul 2020; term ends May 2025 | Audit Committee Chair |
| Seismic Therapeutic | Independent Director | Since Sep 2024 | Audit Committee member; Compensation Committee Chair |
| Harpoon Therapeutics (NASDAQ: HARP) | Director | Oct 2018 – Mar 2024 | Audit Chair 2018–2021 |
| Graybug Vision (NASDAQ: GRAY) | Director | Sep 2020 – Mar 2023 (merged with Calcimedia) | — |
Board Governance
- Classification/term: Class I director up for election at the 2025 Annual Meeting; Board recommends “FOR” her election .
- Committee assignments: Audit Committee member; Audit Committee chaired by Samuel Leno. Lantheus designates Eastland as an “Audit Committee Financial Expert” under SEC rules .
- Independence: Board determined she is independent under Nasdaq and Exchange Act rules; 9 of 11 directors are independent .
- Attendance/engagement: In 2024 the Board met 9 times; Audit met 4 times; each director attended at least 75% of Board and applicable committee meetings. Independent directors hold private executive sessions at most meetings (at least twice per year) .
- Overboarding policy: Lantheus limits CEOs of public companies to no more than two other public boards in addition to Lantheus. Eastland’s disclosed public boards fall within this limit .
Fixed Compensation
| Element | Program Detail (FY24/Director Term) | Eastland 2024 Actual |
|---|---|---|
| Board retainer (cash) | $60,000 annual member retainer; Lead Independent Director $95,000; Board Chair $125,000 (increased from $55k/$117.5k in Apr 2024) | $18,125 cash fees (prorated from Sep 2024) |
| Committee fees (cash) | Audit Chair $25,000; Audit member $12,500; Comp Chair $20,000 / member $10,000; NCG Chair $15,000 / member $7,500; S&T Chair $15,000 / member $7,500 | Included in cash total above (prorated) |
- Compensation governance: Director pay reviewed with independent consultant (Pearl Meyer) and benchmarked to peers; modest increases approved for 2024–2025 term .
Performance Compensation
| Grant Type | Grant Date | Quantity | Grant Date Fair Value | Notes |
|---|---|---|---|---|
| RSUs | Sep 10, 2024 | 1,345 | $133,263 | Prorated annual director grant; unvested at 12/31/24 |
| Stock Options | Sep 10, 2024 | 2,506 | $133,294 | Prorated annual director grant; all unvested at 12/31/24 |
| Annual Equity Program | Timing aligned to Annual Meeting; standard annual equity retainer $400,000 grant-date value for non-employee directors | — | — |
- Ownership alignment: Director stock ownership guideline equals 3x annual Board cash retainer, to be met within 5 years; directors must retain 50% of net-after-tax shares until compliant .
- Hedging/pledging: Prohibited for directors and employees .
Other Directorships & Interlocks
| Potential Interlock Area | Observation |
|---|---|
| Customers/suppliers/competitors | External boards span biotech/vaccines (Zentalis, Dynavax, Seismic), with no disclosed related-party dealings with Lantheus . |
| Time commitments | CEO of a public company with additional board roles; within Lantheus overboarding policy for public-company CEOs . |
Expertise & Qualifications
| Skill Area | Eastland Classification |
|---|---|
| Corporate Finance & Capital Markets | Subject Matter Expertise |
| Accounting & Financial Reporting | Subject Matter Expertise |
| Director/Officer of Public Company | Subject Matter Expertise |
| M&A and Business Development | Meaningful Experience |
| Technology/Cyber/Data Privacy | Meaningful Experience (board matrix) |
- Audit Committee Financial Expert designation under SEC rules supports oversight of financial reporting and controls .
Equity Ownership
| Holder | Shares Beneficially Owned | % Ownership | Notable Unvested/Unexercisable Holdings |
|---|---|---|---|
| Julie Eastland | — | <1% | 1,345 unvested RSUs; 2,506 unvested options (not counted as beneficially owned) |
- Compliance with ownership guidelines: As of Dec 31, 2024, each director either met the guideline or was within the 5-year phase-in period (Eastland falls within phase-in given 2024 appointment) .
Board Governance
| Topic | Detail |
|---|---|
| Committee structure | 100% independent Audit, Talent & Compensation, and Nominating & Corporate Governance committees . |
| Risk oversight | Audit oversees financial reporting, internal controls, cybersecurity; Board committees cover comp risk, ERM/ESG, and science/technology risks . |
| Audit Committee report | Recommended inclusion of FY2024 audited financials in 2024 Form 10-K; confirmed auditor independence . |
Governance Assessment
-
Positives
- Independent director with deep finance and accounting expertise; designated Audit Committee Financial Expert—supports strong financial oversight .
- Clean independence profile; no related-person transactions disclosed involving Eastland; hedging/pledging prohibited .
- Pay structure aligns with market norms and equity-based ownership expectations; 5-year guideline with share retention enhances alignment .
- Attendance and engagement: Board and committee participation thresholds met; regular executive sessions enhance independent oversight .
-
Watch items
- Ownership: No beneficially owned common shares as of Mar 3, 2025; however, recent appointee with unvested awards and a 5-year compliance window—monitor progression toward 3x retainer guideline .
- Time commitments: Concurrent CEO role at Zentalis with additional board seats; remains within Lantheus overboarding limits but should be monitored for bandwidth as transactions/strategy intensify .
-
Conflicts/Related Parties
- Lantheus maintains an Audit Committee-led approval framework for related person transactions; any conflicted committee member must recuse. No specific related-party transactions involving Eastland are disclosed in the proxy .
Overall signal: Eastland brings strong capital markets and accounting expertise to the Audit Committee with an “Audit Committee Financial Expert” designation, bolstering board effectiveness. Her current equity is largely unvested and total ownership is still de minimis given the recent appointment; adherence to the 5-year ownership guideline and continued compliance with overboarding limits will be key investor watchpoints .